EQS Voting Rights Announcement: BB BIOTECH AG
BB BIOTECH AG: Disclosure of Shareholdings

10.05.2024 / 17:40 CET/CEST
Dissemination of a Voting Rights Announcement transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Disclosure of Shareholdings

Published, 08/05/2024

 

Notification ID: 95e58c52-be79-4dff-913a-3d312fe9da73

 

Notification of Collective Investment Schemes

PART 1: LICENSEE

Company name and head office of the licensee resp. for foreign collective investment schemes, which are not authorized for sale and are not dependent from a group of companies, company name and head office of the fund administration or the investment company:

Company: UBS Fund Management (Switzerland) A

City: Basel

Country: Switzerland

 

PART 2: COLLECTIVE INVESTMENT SCHEME/S

Name of collective investment scheme/s which hold/s individually 3% or more voting rights

 

PART 3: DATE AND REASON FOR THE REPORTING OBLIGATION

Date of the act that creates the obligation to notify: 30.04.2024

Date of transfer of equity securities (if different from date of the act which
creates the obligation to notify):

 

Facts and circumstances triggering the obligation to notify (art. 22 para. 1 b FMIO-FINMA):

Acquisition

Sale

Creation of a group

Change in group composition Termination of a group

Discretionary exercise of voting rights

Securities lending and comparable transactions

Exercise, non-exercise or expiration of derivative holdings

Granting (writing) of derivative holdings

Capital increase

Capital reduction

Ipso jure transfer or transfer due to a decision by a court or public authority

Change in the information subject to the obligation to notify

Other X
Disclosure triggered due to the absorption merger (“Absorptionsfusion”) between Credit Suisse Funds AG and UBS Fund Management (Switzerland) AG and the aggregation of the relevant interest of both entities as upon merger Credit Suisse Funds AG ceased to exist and UBS Fund Management (Switzerland) AG was the surviving entity.


Total of voting rights below 3%

If the participation falls below the threshold of 3% (purchase positions and sale positions), no indication in Part 4 or Part 5 is required.

Total of voting rights <3%

 

PART 4: PURCHASE POSITIONS PURSUANT TO ART. 14 PARA. 1 A FMIO-FINMA

 

Total of all purchase positions:

Total of all equity securities or equity related securities (item 1), number of voting rights that can be exercised at one’s own discretion (item 3) and derivative holdings (item 4)

Number of voting rights Percentage
S1 = [1.1] + [3.1] + [4.1] S2 = [1.2] + [3.2] + [4.2]
2,413,177 4.356%

 

Basis of calculation (art. 14 para. 2 FMIO-FINMA): total number of voting rights pursuant to the entry in the commercial register (see Central Business Names Index) or Publication according to art. 115 para. 3 FMIO:

 55,400,000 
 

  1. Equity securities or equity related securities
 
Shares Number Voting rights1
    Number Percentage2
Registered share 2,413,177 2,413,177 4.356%
 
Total		   [1.1]
2,413,177		 [1.2]
4.356%
  1. Whether exercisable or not
  2. Calculated on the basis of the total number of voting rights pursuant to the entry in the commercial register (art. 14 para. 2 FMIO-FINMA)

 

  1. Securities lending and comparable transactions in equity securities

Of the equity securities mentioned in item 1 above, the following part is held due to securities lending and comparable transactions (art. 17 FMIO-FINMA):

 

 
 
Shares		  
 
Number		  
 
Proportion of voting rights		  
Nature of the
legal transaction		 Agreed date of return transfer or, if there is a right to choose, whether this applies to the contracting party subject to the obligation to notify or to
the counterparty

 

  1. Voting rights that can be exercised at one's own discretion

The following voting rights were delegated by a third party and can be exercised at one's own discretion.

 

Voting rights

Is the person who has full discretionary powers to exercise voting rights directly or indirectly controlled?

Yes  No

 
  1. Derivative holdings

Conversion and share purchase rights (such as call-options according to art. 15 para. 2 a FMIO-FINMA), granted (written) share sale rights and other derivative holdings:

 

Type of rights Number of rights Number of voting rights conferred Security ID number (ISIN) if available or basic terms
    Number Percentage2 Identity of issuer, subscription ratio, exercise price,
exercise period, exercise type

[4.1] [4.2]

Total

2 Calculated on the basis of the total number of voting rights pursuant to the entry in the commercial register (art. 14 para. 2 FMIO-FINMA)

 

  1. Securities lending and comparable transactions in derivative holdings

Of the derivative holdings mentioned in item 4 above, the following part is held due to securities lending and comparable transactions (art. 17 FMIO-FINMA):

 

 
 
Nature of the legal transaction		  
 
Number of rights		  
Number of reported voting
rights		  
 
Proportion of voting rights		 Agreed date of return transfer or, if there is a right to choose, whether this applies to the contracting party subject to the obligation to notify or to
the counterparty


PART 5: SALE POSITIONS PURSUANT TO ART. 14 PARA. 1 B FMIO-FINMA

Total of all sale positions: 
Basis of calculation (art. 14 para. 2 FMIO-FINMA): total number of voting rights pursuant to the entry in the commercial register (see Central Business Names Index) or Publication according to art. 115 para. 3 FMIO:

 55,400,000 

 

Derivative holdings

Share sale rights (such as put-options according to art. 15 para. 2 a FMIO-FINMA), granted (written) conversion and share purchase rights and other derivative holdings:

 

Type of rights Number of rights Number of voting rights conferred Security ID number (ISIN) if available or basic terms
    Number Percentage2 Identity of issuer, subscription ratio, exercise price,
exercise period, exercise type

Total

2 Calculated on the basis of the total number of voting rights pursuant to the entry in the commercial register (art. 14 para. 2 FMIO-FINMA)


10.05.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
Language: English
Company: BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Internet: www.bbbiotech.ch

 
End of News EQS News Service

1900663  10.05.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1900663&application_name=news&site_id=boersennews_de~~~d41e2cc8-bdcb-47ba-bb51-c77a04513666